Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.61 |
| ▸ | CA2 | P00918 | 10/20 | 0.61 |
| ▸ | CA9 | Q16790 | 8/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185577 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL186596 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL148281 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL147680 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1655279 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL374532 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10715880 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL143597 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL22283885 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL770634 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | SALIX PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230149389-A1 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-05-18 | — | — | US | disclosed |
| US-20220175764-A1 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-06-09 | — | — | US | disclosed |
| US-4428849-A | ACID-TREATED JPOLYISOBUTENYL SUCCINIMIDES | EXXON RESEARCH & ENGINEERING CO. (US) | 1984-01-31 | — | — | US | disclosed |
| EP-0014288-B1 | PROCESS FOR PRODUCING OIL SOLUBLE DERIVATIVES OF UNSATURATED C4-C10 DICARBOXYLIC ACID MATERIALS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-06-08 | — | — | EP | disclosed |
| US-4338205-A | ACID-TREATED, BORATED ALKENYLSUCCINIMEDE | EXXON RESEARCH & ENGINEERING CO. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4235786-A | REACTION OF POLYISOBUTYLENE AND MALEIC ANHYDRIDE | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-11-25 | — | — | US | disclosed |
| EP-0014288-A1 | Process for producing oil soluble derivatives of unsaturated C4-C10 dicarboxylic acid materials | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1980-08-20 | — | — | EP | disclosed |
| US-4144181-A | GRAFT POLYMER, ETHYLENE, UNSATURATED ACID OR ANHYDRIDE, POLYOL, POLYAMINE, HYDROXYAMINE AND A HYDROCARBYL ACID | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-03-13 | — | — | US | disclosed |
| US-4069162-A | METAL SALT OF WEAK ACID, OIL-SOLUBLE STRONG ACID | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | MTNR1A, OPRL1, OPRK1 | CA1 2143/4885CA2 2836/4885CA9 2604/4885 |
| US-20230149389-A1 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | SLC10A2, OPRL1, OGFR | CA1 1744/4885CA2 911/4885CA9 3200/4885 |
| US-20220175764-A1 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | SLC10A2, SLC10A1, NR1H4 | CA1 4733/4885CA2 3899/4885CA9 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.